Last reviewed · How we verify
NCT06147830: REVERXaL
A Study to Describe the Characteristics, Health Care Interventions and Outcomes of Patients With Major Bleedings in the Presence of Factor Xa Inhibitor Treatment
trial testing None (Observational study) in Major Bleeding in 2,202 participants. Completed in 30 November 2024.
30 November 2024
Quick facts
| Lead sponsor | AstraZeneca |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 2,202 |
| Start date | 4 December 2023 |
| Primary completion | 30 November 2024 |
| Estimated completion | 30 November 2024 |
| Sites | 75 locations across United Kingdom, Japan, United States, Germany |
Drugs / interventions tested
- None (Observational study)
Conditions studied
- Major Bleeding — all drugs for Major Bleeding →
Sponsor
AstraZeneca — full company profile →
Who can join
Adults 18 to 130, any sex, with Major Bleeding. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
REVERXaL study aims to increase the understanding of the patient characteristics, bleeding presentation, health care interventions provided, and the clinical as well as self-reported health outcomes of patients with major bleeding in the presence of Factor Xa inhibitor treatment. The generation of insight on treatment approaches and associated outcomes in hospitalized patients with Factor Xa inhibitor-related major bleeds may inform clinical guidelines, health system decision making and streamline treatment pathways in this population.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Design and rationale for REVERXaL: A real-world study of patients with factor Xa inhibitor-associated major bleeds.
Alikhan R, Nour M, Yasaka M, Ofori-Asenso R, et al · · 2024 · cited 1× · PMID 38905928 · DOI 10.1016/j.thromres.2024.109046 -
Patient characteristics, treatment patterns, and clinical outcomes in patients hospitalized with factor Xa inhibitor-associated major bleeds: A report from the REVERXaL study.
Alikhan R, Nour M, Tiede A, Ofori-Asenso R, et al · · 2026 · PMID 41903429 · DOI 10.1016/j.thromres.2026.109650
Verify or expand the search:
- PubMed search for NCT06147830
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of None (Observational study)
Trials testing the same drug.
- NCT07346768 — Evaluation of Anterior Neck Ultrasound in Predicting Difficult Airway in Obese Patients · not yet recruiting
- NCT07141277 — GRANITE: Airsupra Effectiveness in the Real World · recruiting
- NCT06222957 — The Effects of HER2 Receptor Signaling on Human Brown Fat Activity · recruiting
- NCT06527872 — Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN · recruiting
- NCT06607068 — Assessment of Taurine Concentration in Older Women With/Without Obesity And With/Without Type 2 Diabetes Mellitus · active not recruiting
Other recruiting trials for Major Bleeding
Currently open trials in the same condition.
- NCT07039149 — Pretreatment of Acute Coronary Syndrome With Dual Antiplatelet Agents · recruiting
Other AstraZeneca trials
Trials by the same sponsor.
- NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
- NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
- NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
- NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
- NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06147830 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
- Last refreshed: 3 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06147830.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing